SBRT and prostatectomy show comparable cancer control in PACE-A; FDA fast-tracks pre-biopsy PSMA-PET

A clear specimen cup of pale liquid with a test strip leaning in it and its screw lid set beside it.

Eight-year results of the PACE-A trial, presented Sept. 28 at the American Society for Radiation Oncology meeting, showed comparable cancer control after stereotactic body radiotherapy (SBRT) and radical prostatectomy, with less incontinence after SBRT. The Food and Drug Administration (FDA) granted fast track designation to a phase 3 program testing prostate-specific membrane antigen (PSMA) PET before biopsy.

The weekly innovation roundup for urology, published every Sunday for the week before; every item links to its sources. Latest urology news · All specialties

Latest news

Tagged urology, from the daily briefing

  1. Phase 3 PACE-NODES trial reports early adverse events for pelvic nodal plus prostate SBRT versus prostate-only SBRT
  2. Lancet Oncology reports the American Cancer Society's updated prostate cancer screening guideline
  3. AUA and SMSNA amend their guideline on disorders of ejaculation

See all the latest news